Biodexa Plc (BDRX), Monday announced the approval of a Clinical Trial Application by the European Medicines Agency of its pivotal Phase 3 Serenta trial in patients with familial adenomatous polyposis.
The CTA permits the Serenta trial to proceed in Europe, initially covering clinical sites in Denmark, Germany, Netherlands and Spain with Italy expected to be added in due course.
The company expects to enroll first European patient in the fourth quarter of 2025.
This approval marks an important milestone for the company's Phase 3 program of eRapa, a proprietary oral capsule formulation of rapamycin, also known as sirolimus.
Currently, Biodexa's stock is falling 12.89 percent, to $5.54 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.